ADA 2026

Representative image of a physician reviewing glucose trend data with a diabetes patient, reflecting Cirius Therapeutics’ CIR-0602K research and the growing search for new insulin-sensitizing therapies beyond GLP-1 drugs.

Pharma & Biotech

Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

by Pallavi Madhiraju
June 2, 2026
0 Comments

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Read More

Representative image: Genentech’s obesity drug data update at ADA 2026 underscores rising interest in enicepatide, petrelintide and next-generation weight management therapies.

Pharma & Biotech

Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?

by Pallavi Madhiraju
June 1, 2026
0 Comments

Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.

Read More